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Abstract
The inherited peroxisomal disorder X-linked adrenoleukodystrophy (X-ALD), associated with neurodegeneration and
inflammatory cerebral demyelination, is caused by mutations in the ABCD1 gene encoding the peroxisomal ATP-binding
cassette (ABC) transporter ABCD1 (ALDP). ABCD1 transports CoA-esters of very long-chain fatty acids (VLCFA) into
peroxisomes for degradation by b-oxidation; thus, ABCD1 deficiency results in VLCFA accumulation. The closest homologue,
ABCD2 (ALDRP), when overexpressed, compensates for ABCD1 deficiency in X-ALD fibroblasts and in Abcd1-deficient mice.
Microglia/macrophages have emerged as important players in the progression of neuroinflammation. Human monocytes,
lacking significant expression of ABCD2, display severely impaired VLCFA metabolism in X-ALD. Here, we used
thioglycollate-elicited primary mouse peritoneal macrophages (MPMW) from Abcd1 and Abcd2 single- and double-deficient
mice to establish how these mutations affect VLCFA metabolism. By quantitative RT-PCR, Abcd2 mRNA was about half as
abundant as Abcd1 mRNA in wild-type and similarly abundant in Abcd1-deficient MPMW. VLCFA (C26:0) accumulated about
twofold in Abcd1-deficient MPMW compared with wild-type controls, as measured by gas chromatography-mass
spectrometry. In Abcd2-deficient macrophages VLCFA levels were normal. However, upon Abcd1/Abcd2 double-deficiency,
VLCFA accumulation was markedly increased (sixfold) compared with Abcd1-deficient MPMW. Elovl1 mRNA, encoding the
rate-limiting enzyme for elongation of VLCFA, was equally abundant across all genotypes. Peroxisomal b-oxidation of C26:0
amounted to 62% of wild-type activity in Abcd1-deficient MPMW and was significantly more impaired (29% residual activity)
upon Abcd1/Abcd2 double-deficiency. Single Abcd2 deficiency did not significantly compromise b-oxidation of C26:0. Thus,
the striking accumulation of VLCFA in double-deficient MPMW compared with single Abcd1 deficiency was due to the loss of
ABCD2-mediated, compensatory transport of VLCFA into peroxisomes. We propose that moderate endogenous expression
of Abcd2 in Abcd1-deficient murine macrophages prevents the severe metabolic phenotype observed in human X-ALD
monocytes, which lack appreciable expression of ABCD2. This supports upregulation of ABCD2 as a therapeutic concept in
X-ALD.
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Introduction
X-linked adrenoleukodystrophy (X-ALD, OMIM #300100) is
an inherited, neurodegenerative disease with variable clinical
presentation. Childhood cerebral ALD (CCALD) with rapidly
progressive cerebral inflammation and demyelination and adult-
hood adrenomyeloneuropathy (AMN), characterized by slowly
progressive spastic paraparesis, are the two most prominent
clinical phenotypes of X-ALD in males [1–3]. In heterozygous
female carriers X-ALD manifests as a milder variant with
myelopathy and/or neuropathy [4], while homozygous females
are extremely rare. All forms of X-ALD are caused by mutations
in the ATP-binding cassette transporter sub-family D (ALD)
member 1 (ABCD1) gene. The encoded protein, ABCD1
(formerly adrenoleukodystrophy protein, ALDP), constitutes a
half-transporter in the peroxisomal membrane [5]. ABCD1
mediates the transport of CoA-activated very long-chain fatty
acids (VLCFA; carbon chain$22 C) into peroxisomes, where they
are degraded by b-oxidation [6,7]. Accumulation of saturated
VLCFA, in particular C26:0, in the plasma and tissues of human
X-ALD patients is a characteristic biochemical and diagnostic
feature of the disease [8].
The endogenous biosynthesis of VLCFA by elongation of long-
chain fatty acids (LCFA) accounts for the major pool of VLCFA in
human X-ALD patients [9,10] with only a minor contribution
from dietary sources [11]. The enzyme family, elongation of very
long-chain fatty acids (ELOVL), mediates the substrate-selective
step of the elongation pathway [12]. ELOVL1 was identified to
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catalyze the synthesis of both saturated (C26:0) and monounsat-
urated (C26:1) VLCFA in human fibroblasts [13].
The capacity for peroxisomal b-oxidation of saturated VLCFA
is reduced in patients with X-ALD [14] as well as in Abcd1-
deficient mice [15–17]. In human fibroblasts, ABCD1 deficiency
leads to impaired transport of CoA-esters of VLCFA across the
peroxisomal membrane [7]. As a result, the majority of VLCFA
escapes degradation via peroxisomal b-oxidation and accumulates
in X-ALD conditions. Moreover, the accumulating VLCFA can
serve as substrates for ELOVL1, which promotes further increase
in chain length and amount of VLCFA culminating with peak
levels of C26:0 [13,18]. The excess of VLCFA leads to
disturbances of intracellular metabolism to varying extent
depending on the cell type. Such perturbations may result in
alterations of membrane structure, stability and function [19–21],
oxidative stress [22,23], energy metabolism [24,25] and increased
expression of inducible nitric oxide synthase [26,27].
Another peroxisomal ATP-binding cassette (ABC) transporter,
ABCD2 (formerly adrenoleukodystrophy-related protein,
ALDRP), encoded by the ABCD2 gene, is the closest homologue
of ABCD1 [28]. Overexpression of ABCD2 has been shown to
functionally compensate for the impairment in peroxisomal b-
oxidation and VLCFA accumulation resulting from ABCD1
deficiency in human X-ALD fibroblasts and in Abcd1-deficient
mice [29–31]. Furthermore, expression of the human ABC
transporters in a heterologous yeast system indicated different
but overlapping substrate specificities for ABCD1 and ABCD2
[6,32]. However, little is known about the endogenous capacity for
cross-compensation between ABCD1 and ABCD2 under condi-
tions of insufficiency in vivo. In Abcd2-deficient mice, saturated
VLCFA do not generally accumulate; increased C26:0 levels have
been detected exclusively in the dorsal root ganglia of young
Abcd2-deficient mice [33]. Instead, accumulation of some
saturated LCFA and monounsaturated fatty acids; in particular
C20:0 and v9-monounsaturated fatty acids was reported in several
tissues of Abcd2-deficient mice including liver, adrenal gland and
sciatic nerve. In other tissues, like spinal cord, the abundance of
these fatty acids was normal; and in Abcd1/Abcd2-double deficient
mice only the level of C22:1v9 was elevated compared with Abcd1
and Abcd2 single deficient mice [34].
Currently, there is no curative therapy available for most X-
ALD patients [35]. Allogeneic bone marrow transplantation or
hematopoietic stem cell transplantation [36,37] and also gene
therapy of autologous CD34+ hematopoietic stem cells, providing
intact ABCD1, can arrest the inflammatory cerebral demyelin-
ation in patients at early stages of cerebral ALD [38]. The
beneficial effects observed upon transplantation and gene therapy
of CD34+ hematopoietic stem cells suggest an involvement of the
bone marrow-derived macrophages and microglia in this process
[39].
In human monocytes/macrophages, ABCD2 is virtually not
expressed [40] and, therefore, cannot compensate for the
functional loss of ABCD1 resulting in a severe metabolic
phenotype in this cell lineage of X-ALD patients [41]. Interest-
ingly, in the perilesional white matter surrounding demyelinating
brain lesions in cerebral ALD, microglia, the resident macro-
phages of the brain, are particularly vulnerable to neurotoxicity
and apoptosis [42], as reviewed in [43]. Furthermore, in X-ALD,
VLCFA were found to be enriched in the lysophosphatidylcholine
(LPC) fraction [44]; and C24:0-containing LPC elicited microglial
activation and apoptosis when injected into the cerebral cortex of
mice [42]. In comparison to other sources of murine macrophages
or microglia, large numbers of primary macrophages can be
obtained from the peritoneal cavity after stimulation with
thioglycollate [45,46], permitting biochemical studies of VLCFA
metabolism in primary macrophages of targeted mouse mutants.
These preparations are highly enriched for macrophages and after
adherence to plastic culture dishes, most of the cells are positive for
the macrophage markers F4/80 or CD11b. In addition to
macrophages, some eosinophils, which also express these surface
markers, may be present [47]. The vast majority of thioglycollate-
elicited primary mouse peritoneal macrophages (MPMF) are
derived from monocytes that are recruited into the peritoneum
and partially activated by the inflammatory stimulus. These differ
in size, surface markers and function from the residential
peritoneal macrophages but show similar phagocytic activity
[48]. Genome-wide transcriptome analysis indicates that thiogly-
collate-induced macrophages are closely related to microglial cells
as well as to bone marrow derived macrophages [49].
Here, we used MPMW to study the contribution of endogenous
Abcd2 expression to VLCFA metabolism in the macrophage-
lineage under Abcd1 deficiency. We determined the mRNA levels
for the peroxisomal fatty acid transporters ABCD1 and ABCD2,
as well as for the fatty acyl chain-elongating enzyme ELOVL1, in
primary macrophages from wild-type and mutant mice with single
or combined Abcd1 and Abcd2 deficiencies. Next, we established
how these expression patterns correlate with the extent of
accumulation and the capacity for degradation of VLCFA. Our
results indicate a strong compensatory effect of ABCD2 on the
metabolic phenotype of Abcd1-deficient murine macrophages.
Materials and Methods
Ethics Statement
The care, handling and experiments involving mice were
carried out in accordance with the national (Austrian) regulations
(BGBl. II Nr. 522/2012) and the directive 2010/63/EU of the
European Parliament and the council of the European Union. All
procedures were reviewed and approved by the local Animal Care
and Use Committee of the Medical University of Vienna and by
the Austrian Ministry for Science and Research (BMWF-66.009/
0100-II/3b/2013). Mice were euthanized by CO2 inhalation
before isolation of peritoneal macrophages.
Animals
Mice with a targeted inactivation (knock-out) of the Abcd1 gene
(B6.129-Abcd1tm1Kan) have been described previously [15]. Mice
with a null mutation in the Abcd2 gene (B6.129-Abcd2tm1Sfp) were
generated as described below. Both mutations had been
backcrossed onto the C57BL/6J background for at least twelve
generations, before cross-breeding to generate Abcd1 and Abcd2
single- and double-deficient mutants and wild-type littermates for
this study. Mice of the different allelic combinations appeared at
the expected frequencies, were viable and developed on schedule
without any overt phenotypical abnormalities. Adult (3 to 6-
months-old) male mice were used for isolation of primary
peritoneal macrophages. The genotype was determined at
weaning and confirmed at sacrifice of experimental animals by
standard PCR analysis using the following primers: for Abcd1,
forward 59-TGTCGGGCGTAGACGCTGTCGT-39 in combi-
nation with reverse 59-CAGGACCACAGCTGTGCGCTTC-39
for the wild-type allele (yielding a 597-bp PCR product) and
reverse 59-GCCTTCTATCGCCTTCTTGACGAG-39 for the
knock-out (neomycin resistance gene, neo) allele (yielding a 210-bp
PCR product); and for Abcd2, forward 59-
TTCTAAGTGCCGCTGAGCATGC-39 in combination with
reverse 59-CTGCTGCATTTAGCATGTGTATC-39 for the
wild-type allele (yielding a 466-bp PCR product) and reverse 59-
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CCATCTTGTTCAATGGCCGATC-39 for the knock-out (neo)
allele (yielding a 322-bp PCR product). All mice for this study were
bred and maintained at the local animal facility of the Medical
University of Vienna. Mice were housed under standard
conditions on a 12/12 h light/dark cycle in a temperature and
humidity–controlled environment with standard mouse chow diet
and water ad libitum.
Construction of the Abcd2 targeting vector
A mouse 129/SvJ genomic library (lFIXII; Stratagene) was
screened with a probe covering nucleotides 1621,078 of the
murine Abcd2 cDNA (GenBankTM Accession No. NM 011994).
From a phage l-clone containing 17 kb of the Abcd2 gene,
including exon 1 through intron 3 and 3.5 kb of 59-flanking DNA,
genomic DNA fragments were subcloned into plasmids to generate
a gene-replacement vector for positive-negative selection [50]. The
final targeting construct (Fig. 1A) contained in 59 to 39 order: a
2.2-kb XhoI2NdeI fragment carrying the thymidine kinase gene
from pMC1TK (Stratagene); a 2.1-kb NdeI2 SphI fragment (2
2.5 kb to 2422 relative to the translation start site of Abcd2)
representing the 59 (short) Abcd2 homology region, adapted with a
39 HindIII site; a 1.15-kb neo gene cassette from pMCneopA
(Stratagene) adapted with 39 HindIII sites; and a 6-kb HindIII2
NotI fragment accommodating the 39 (long) Abcd2 homology
region [from HindIII (+816) in exon 1 to XhoI in intron 3, cloned
into a polylinker with a NotI site] inserted between SalI and NotI
of the pBluescript KSII (Stratagene) vector backbone. Thus, the
neo cassette replaces a 1,238-bp region of the Abcd2 gene, between
SphI (2422) andHindIII (+816), which contains the promoter and
most of exon 1. Both neo and thymidine kinase were inserted in
sense orientation relative to Abcd2 (Fig. 1A).
Generation of Abcd2-deficient mice
Mouse RI embryonic stem (ES) cells [51], kindly provided by A.
Nagy (Toronto), were transfected by electroporation using 50 mg
of the NotI-linearized targeting vector. Colonies were isolated after
G418/gancyclovir selection as previously described [50,52].
Double-resistant clones resulting from homologous recombination
were identified by PCR amplification of a 3.1-kb genomic Abcd2-
neo junction fragment from DNA of heat-lysed cells using Abcd2
forward primer (59-AGGATCTGCTTAAGAGTTCCACT-39) at
position P1, flanking the homology region, and neo reverse primer
(59-CCATCTTGTTCAATGGCCGATC-39) at position P2 (as
indicated in Fig. 1A). The initial denaturation at 94uC for 3 min
was followed by 32 cycles of PCR (denaturation at 94uC for 30 s,
annealing at 61uC for 30 s, and extension at 72uC for 2 min) and
final extension at 72uC for 2 min. Individual PCR-positive clones
were expanded and homologous recombination was confirmed by
Southern blot analysis of ScaI-digested DNA (8 mg/sample) using
a digoxygenin-labelled hybridization probe (indicated in Fig. 1A)
derived from the 59-flanking region, upstream from the neo
insertion.
Microinjection of selected ES cells into C57BL/6J blastocysts
and embryo transfer to foster mothers were performed by standard
procedures. Resulting chimeras were mated with C57BL/6J mice
and germ line-transmission was obtained from one founder.
Heterozygous (Abcd2+/2) F1 mice were again crossed with
C57BL/6J mice and F2 heterozygous mutants were interbred to
generate homozygous (Abcd22/2) mice in the F3 generation. The
Abcd2 genotype of these mice was determined by allele-specific
PCR and Southern blot analyses using genomic DNA (Fig. 1B) as
outlined for ES cells.
RNA analyses for verification of functional disruption of
Abcd2
Northern blot analysis was used to confirm the absence of
functional Abcd2 gene expression in Abcd22/2 mutant mice. Total
RNA was isolated from flash frozen tissues [53] of 2.5-months-old
Abcd2+/+ and Abcd22/2 littermates. For each sample, the polyA+-
RNA fraction (approximately 2 mg) obtained by oligo(dT) selection
of 100 mg total RNA was size-separated on formaldehyde-agarose
gels to prepare northern blots as previously described [54]. A gene-
specific, [a-32P]dCTP-labelled hybridization probe covering exon
1 was generated by random priming with Abcd2 cDNA as a
template. As a control of loading and transfer, the blot was
stripped and reprobed with b-actin cDNA. All blots were washed
to high stringency (at 68uC in 0.2 x SSC, 0.2% SDS) and
monitored with a phoshorimager (Molecular Imager FX System,
Bio-Rad).
For end point RT-PCR analysis of Abcd2 mRNA expression in
MPMF, total cellular RNA was isolated and reverse transcribed as
described for the qRT-PCR analysis (see below). Diluted cDNA,
corresponding to 4 ng of total RNA, was applied for 35 cycles of
PCR using GoTaq polymerase (Promega) with Abcd2 forward
primer (59-GAAGCCTCGGACTTTCATCATC-39) and reverse
primer (59-GTGTAATTATGGGAACATTTTCAC-39) from ex-
on 1 and exon 5, respectively, at an annealing temperature of
59uC, to generate a 1,051-bp product in Abcd2+/+ cDNA samples.
No amplicon was observed when reverse transcriptase was omitted
or when genomic DNA was used as template. As a positive control,
the macrophage marker ionized calcium-binding adapter molecule
1 (Iba1), also known as allograft inflammatory factor 1 (Aif1), was
amplified from the same cDNA samples under identical condi-
tions, except that annealing was at 54uC, with Iba1 forward
primer (59-AGAAGAGACTGGGGAGCTGGT-39) from exon 3
and reverse primer (59-CCAAGTTTCTCCAGCATTCGC -39)
from exon 7 (based on GenBankTM Accession No. NM 019467.2)
generating a specific 310-bp PCR product.
Isolation and Cell Culture of Mouse Peritoneal
Macrophages
Primary mouse peritoneal macrophages (MPMW) were isolated
from wild-type and knock-out mice as described in [55] with some
minor modifications. Briefly, mice were injected intraperitoneally
with 2 ml of 4% thioglycollate medium (Sigma). Four days later,
mice were sacrificed for peritoneal lavage with 10 ml of complete
medium [RMPI-1640 medium (PAA) supplemented with 10%
fetal bovine serum (PAA), 100 units/ml each of penicillin and
streptomycin (Lonza) and 2.5 mg/ml Fungizone (Gibco)] using a
syringe with a 23G needle. The recovered cells were centrifuged at
3006g at 4uC for 10 min; the supernatant was aspirated and the
cell pellet resuspended and washed twice in 10 ml complete
RPMI-1640 medium. Finally, cells were counted and the required
numbers were plated and cultured at 37uC with 5% CO2 for 4 h,
during which the MPMW attach to the cell culture plate
(CELLSTAR, Greiner Bio-One) while the vast majority of other
cell types from the peritoneal lavage remain in suspension and are
removed by aspiration. After this incubation period, the attached
MPMW were washed with phosphate buffered saline (PBS) and
used according to the experimental requirements. Unless stated
otherwise, the cells were maintained for 20 h in complete medium
at 37uC with 5% CO2 before harvesting.
Endogenous Abcd2 Compensates Abcd1 Deficiency in Murine Macrophages
PLOS ONE | www.plosone.org 3 September 2014 | Volume 9 | Issue 9 | e108655
Figure 1. Strategy and molecular evidence for targeted inactivation of the Abcd2 gene. (A) Structure of the 59 region of the Abcd2 gene,
the targeting construct and the disrupted gene. Exons (Ex) 1–3 are depicted as boxes with the protein coding region in gray. After homologous
recombination, 1.24 kb of the Abcd2 gene, including the transcription and translation start sites and most of exon 1, is replaced by the neomycin
resistance gene cassette (Neo) of the targeting construct. Positions of the PCR primers (P1, P2) and the Southern blot probe (****) used in genotyping
to detect homologous recombination are indicated. Restriction sites used for cloning or analysis are marked: H, HindIII; N, NdeI; Not, NotI; S, ScaI; Sp,
SphI and X, XhoI. (B) Southern blot analysis of ScaI-digested DNA from Abcd22/2, Abcd2+/+ and Abcd2+/2 mice. Chemiluminescent detection of a
digoxygenin-labelled probe from the 59 flanking DNA verified homologous recombination based on deletion of a ScaI-site in exon 1 of Abcd2
resulting in 3.9-kb and 4.4-kb fragments from the wild-type (WT) and knock-out (KO) alleles, respectively. (C) Northern blot analysis of mRNA from
brain and skeletal muscle of adult Abcd22/2 and Abcd2+/+ mice. A 32P-labelled Abcd2 cDNA probe hybridized to the major 4.2 kb Abcd2 mRNA and
minor (5.5 and 2.8 kb) variants in both tissues of wild-type mice, but not in Abcd22/2 mice. As a loading control, the blot was re-probed with b-actin
cDNA, which in skeletal muscle detects a shorter, more abundant mRNA than in brain. (D) Reverse transcription-coupled PCR analysis of Abcd2 mRNA
expression in primary peritoneal macrophages from two Abcd2+/+ and two Abcd22/2 mice. Abcd2-specific primers amplified the expected 1,051-bp
product in Abcd2+/+ but not in Abcd22/2 macrophages. As a positive control, amplification of Iba1 cDNA (310-bp fragment) was confirmed in all
samples.
doi:10.1371/journal.pone.0108655.g001
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RNA isolation and quantitative reverse transcription-
coupled PCR (qRT-PCR)
MPMW (36105 cells/well) were seeded in 6-well cell culture
plates. At harvest, the attached MPMW were washed with PBS
and total RNA was isolated using the RNeasy Mini kit (Qiagen),
including on-column DNA digestion with RNase-free DNase
(Qiagen), according to the manufacturer’s instructions. RNA
concentrations were determined using a NanoDrop spectropho-
tometer (PEQlab). Total RNA (80 ng) was reverse transcribed into
cDNA in 20 ml final volume using the iScriptTM cDNA synthesis
kit (Bio-Rad) at 25uC for 5 min, 42uC for 30 min and 85uC for
5 min and holding at 4uC. The cDNA was diluted 1:5 and 5-ml
aliquots were applied for two-step qRT-PCR (denaturation at
95uC, annealing/extension at 60uC) using SsoFast EvaGreen
Supermix (Bio-Rad) and the CFX96 Real-Time PCR Detection
System (Bio-Rad) according to the manufacturer’s recommenda-
tions together with the following gene specific primer combina-
tions: Hprt, forward 59-ACTTCAGGGATTTGAATCACGTT-
39 and reverse 59-GCAGATGGCCACAGGACTAGA-39, prod-
uct size 154 bp; Abcd1, forward 59-GCTGTGACCTCCTA-
CACTCTCC-39 and reverse 59-AGTAGTGCCAGTTC-
CACCTCA-39, product size 251 bp; Abcd2, forward 59-
GAACTACCCCTCAGCGACAC-39 and reverse 59-
ATGGCCTCTGTGGAATATAGAAC-39, product size 280 bp;
and Elovl1, forward 59-ATTGAGCTGATGGACACAGTGAT-
39 and reverse 59-GACCAGGACAAACTGGATCAGC-39, prod-
uct size 279 bp.
The absolute quantification of each mRNA was based on
standard curves, which were generated from serial dilutions of
known copy numbers of linearized plasmids containing the
corresponding cDNA region of murine Abcd1, Abcd2, Elovl1 or
Hprt. The quantity obtained for each mRNA after reverse
transcription to cDNA (Table S1 and Table S2) was normalized to
that of Hprt in order to compensate for variation in amount of
total RNA and/or cDNA conversion between samples.
VLCFA measurements
Deuterium-labelled VLCFA standards: [3,3,5,5-2H4]-hexacosa-
noic acid (2H4-C26:0), [3,3,5,5-
2H4]-tetracosanoic acid (
2H4-
C24:0) and [3,3,5,5-2H4]-docosanoic acid (
2H4-C22:0) were
obtained from Dr. Herman J. ten Brink (Free University Hospital,
Amsterdam, The Netherlands); and [7,7,8,8-2H4]-palmitic acid
(2H4-C16:0) was from Cambridge Isotope Laboratories Inc.
(Andover, MA, USA); and the unlabelled fatty acids C26:0,
C24:0, C22:0, and C16:0 were from Sigma-Aldrich.
For each sample, 5276106 peritoneal cells were seeded in one
culture plate and maintained in complete medium for either 1 day
or 5 days. At harvest, the MPMW were washed three times with
PBS and pelleted. Cell pellets were suspended in distilled water
and sonicated three times for 30 s on ice. Protein concentration
was determined by the method of Lowry using bovine serum
albumin (Sigma-Aldrich) as standard [56]. Extraction and
quantitative analysis of fatty acids by gas chromatography-mass
spectrometry (GC-MS) were carried out as previously described
[57]. GC-MS measurements were carried out in a TRACE MS
Plus gas chromatograph single quadrupol mass spectrometer
(Thermo Fisher Scientific) equipped with a J&W Scientific DB-
1ms capillary column (30 m x 0.25 mm I.D., film thickness
0.25 mm; Agilent Technologies). Data were analyzed with the
Finnigan XcaliburTM software package (Thermo Fisher Scientific)
using calibration curves obtained from unlabelled fatty acids in the
concentration range from 0.005 to 0.2 mg/ml for C26:0, from 0.25
to 2.5 mg/ml for C22:0 and C24:0, and from 5 to 100 mg/ml for
C16:0.
b-Oxidation of 1-14C-labelled fatty acids
The MPMW obtained after selective adherence of 26106
peritoneal cells, seeded in one culture plate and maintained in
complete medium for 20 h, were washed with PBS before
harvesting and resuspending in 200 ml of buffer (250 mM sucrose,
10 mM Tris-Cl, pH 8.0). The protein concentration was mea-
sured in an aliquot of each sample using the CBQCA Protein
Quantitation Kit (Molecular Probes). To determine the b-
oxidation activity for C26:0 and C16:0, aliquots of 100 ml and
33 ml were used, respectively.
Radiolabelled 1-14C palmitic acid (C16:0; ARC 0172A) and
1-14C hexacosanoic acid (C26:0; ARC 1253) were obtained from
American Radiolabeled Chemicals. Free fatty acids in ethanol
were aliquoted into glass reaction tubes, dried under a stream of
nitrogen and solubilized in 10 mg/ml a-cyclodextrin by ultra-
sonication. b-Oxidation of labelled fatty acids to acetate was
carried out according to [58] with modifications as described
previously [7]. Briefly, for each sample the reaction mix of 250 ml
contained 4 mM radiolabelled fatty acid (either C16:0 or C26:0),
2 mg/ml a-cyclodextrin, 250 mM sucrose, 30 mM KCl, 20 mM
Tris-Cl (pH 8.0), 8.5 mM ATP, 8.5 mM MgCl2, 2.5 mM l-
carnitine, 1 mM DTT, 1 mM NAD+, 0.5 mM malate, 0.2 mM
EDTA, 0.17 mM FAD, 0.16 mM CoA and cell preparation (as
described above). Reactions were started by addition of cellular
protein, incubated for 1 h at 37uC and stopped by adding KOH
and heating at 60uC for 1 h. After protein precipitation by
HClO4, a Folch partition was carried out and the amount of
14C-
acetate in the aqueous phase was determined in a scintillation
counter.
Statistical analyses
Statistical analyses were carried out either with two-tailed t-test
or one-way analysis of variance (ANOVA) with appropriate post-
hoc test. Statistical analyses for VLCFA were performed on log-
transformed data using one-way ANOVA followed by Tukey’s
post-hoc test. Thereafter, these data were back-transformed to
obtain and represent the geometric means with error bars showing
the asymmetrical standard deviations. Statistical analyses for b-
oxidation assays were performed using one-way ANOVA followed
by Tukey’s post-hoc test. Data from b-oxidation assays and qRT-
PCR are represented as arithmetic means 6 standard deviation
(SD). Differences in mean values were considered statistically
significant at p,0.05.
Results
Targeted inactivation of the murine Abcd2 gene
To study the compensatory role of Abcd2 in tissues and distinct
cell types of X-ALD mice, we generated mice with a null mutation
in the Abcd2 gene by applying a similar strategy as previously used
for the targeted inactivation of Abcd1 [15]. Briefly, the targeting
vector for homologous recombination in mouse ES cells was
constructed from isogenic (129Sv) DNA encompassing the 59
region of the murine Abcd2 gene (Fig. 1A). Between the ‘‘short
arm’’ (3.5 kb of DNA upstream from exon 1) and the ‘‘long arm’’
(6 kb from the 39 end of exon 1 through intron 3) of the targeting
vector, 1,238 bp of the Abcd2 gene containing 250 bp of the
promoter region and most of exon 1 were replaced by a neo gene
cassette, which also served as a marker for positive selection. This
deletion eliminates the transcription and translation start sites and
the coding capacity for the 272 amino-terminal amino acids of
ABCD2 [59]. A thymidine kinase gene cassette was inserted 59 to
the homology region for negative selection against random
integration events. ES cells were transfected with the targeting
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vector and double (G418, gancyclovir)-resistant recombinant
clones selected, of which 10% were identified by PCR to result
from homologous recombination. Correct gene targeting was
confirmed by Southern blot analysis discriminating between wild-
type (Abcd2+) and disrupted (Abcd22) alleles based on the loss of a
diagnostic ScaI restriction site in exon 1 (Fig. 1A).
Germline chimeras were obtained from a correctly targeted ES
clone injected into C57BL/6 blastocysts. The progeny obtained
after breeding of this founder and subsequent generations with
C57BL/6J mice gave rise to a permanent mouse line (B6.129-
Abcd2tm1Sfp) carrying the disrupted Abcd2 gene (here referred to
as Abcd2-deficient, Abcd22/2, or Abcd2 knock-out). The genotype
was initially determined by PCR (data not shown) and Southern
blot analysis (Fig. 1B) to confirm the gene structure expected after
a unique homologous recombination event. Heterozygous and
homozygous animals were obtained at the expected Mendelian
ratios and were viable, fertile and developed into adults with
normal home cage behaviour and healthy appearance. Starting
around 12 months of age, Abcd22/2 mice developed a sensory–
motor impairment (data not shown), which has been reported
previously in an independent Abcd2-deficient mouse strain
[31,33]. This ataxic phenotype developed with a similar age-of-
onset also in Abcd1/Abcd2 double-deficient mice.
Loss of Abcd2 mRNA expression in gene targeted mice
To verify that homologous recombination had inactivated
functional expression of Abcd2, we assessed the presence of Abcd2
mRNA by Northern blot analysis in brain and skeletal muscle, two
tissues in which Abcd2 is normally abundantly expressed [60]. The
Abcd2-specific cDNA probe detected the major 4.2 kb Abcd2
mRNA, as well as the minor 5.5 and 2.8 kb transcripts arising
from alternative polyadenylation sites, in both tissues of wild-type
but not Abcd22/2 mice (Fig. 1C). The loading control, b-actin,
gave similar signals in corresponding wild-type and knock-out
tissues.
The absence of Abcd2 mRNA was also verified in primary
mouse peritoneal macrophages (MPMF) isolated from Abcd22/2
mice by end point RT-PCR using total cellular RNA. In wild-type
cells, RT-PCR with Abcd2-specific primers robustly amplified the
expected product, whereas no signal was obtained in Abcd22/2
MPMF (Fig. 1D). As a positive control for the quality of the
RNA/cDNA preparations, the macrophage marker Iba1 could be
easily amplified in all cDNA samples. Taken together, these
expression studies confirm the absence of functional Abcd2 mRNA
in cells and tissues of the Abcd2 knock-out mice, validating that the
gene disruption generated a null mutation.
By cross-breeding the Abcd1- and Abcd2-deficient mutant
strains, we generated mice with single and combined Abcd1/
Abcd2-deficiencies and appropriate wild-type littermate controls,
all on the C57BL/6J background. Mice of the different allelic
combinations appeared at the expected frequencies, were viable
and reached adulthood without overt phenotypical abnormalities.
In the present study only young male mice were used as donors of
thioglycollate-elicited peritoneal macrophages, because in X-
linked ALD, predominantly the male (hemizygous) patients are
severely affected.
Abcd2 mRNA is expressed at half the level of Abcd1
mRNA in mouse peritoneal macrophages
First, we explored the basal expression of the Abcd1 and Abcd2
genes in MPMW collected from wild-type mice and then compared
these with the levels in Abcd1 and Abcd2-deficient MPMW. The
absolute quantity of each mRNA was determined by qRT-PCR
analysis and normalized to the level of Hprt mRNA (Fig. 2A and
Table S1). In wild-type cells, both mRNAs were detected at low
abundance; however, the Abcd2 mRNA was present at 58% of the
level of the Abcd1 mRNA (Fig. 2A). Because we had previously
found Abcd2 mRNA expression to be altered in hepatic tissue of
Abcd1-deficient mice [61], we determined the Abcd2 mRNA levels
in Abcd1-deficient MPMW in order to uncover any potential
compensatory dysregulation. However, there was no statistically
significant difference between the Abcd2 mRNA levels of wild-type
and Abcd1-deficient MPMW (Fig. 2B). Vice versa, the Abcd1
mRNA remained at wild-type level in MPMW from Abcd2-
deficient mice (Fig. S1).
Inactivation of Abcd2 alone has no impact on VLCFA
levels of MPMW but a strong synergistic effect in
combined Abcd1/Abcd2 deficiency
MPMW isolated from mice with single or combined Abcd1 and
Abcd2 deficiency or from wild-type littermates were cultured for
either one or five days before harvesting for fatty acid analysis. The
amounts of VLCFA (C26:0, C24:0, C22:0) and LCFA (C16:0)
were measured by GC-MS. First, we established the extent of
accumulation of saturated VLCFA in Abcd1-deficient MPMW.
Compared with wild-type levels, we found a two-fold increase in
the ratio C26:0/C22:0 (Fig. 3A). There was no statistically
significant difference in the C26:0/C22:0 ratio of Abcd2-deficient
MPMW when compared with wild-type. However, we noticed
strikingly increased accumulation of C26:0 in MPMW from Abcd1/
Abcd2 double-deficient mice, as judged by the ratio C26:0/C22:0
(Fig. 3A) as well as the absolute amounts (Fig. S2). The difference
in accumulation (C26:0/C22:0) was statistically highly significant
in comparison with wild-type or Abcd2-deficient or even with
Abcd1-deficient samples (p,0.001). We observed similar C26:0/
C22:0 profiles in MPMW harvested after five days (Fig. 3A) or
after one day (Fig. S3) in cell culture. Because the level of C22:0
remains unaltered or even drops somewhat in X-ALD, we also
established the levels of C16:0 in all samples, as an additional
reference for comparisons of the different VLCFA species, in
addition to their absolute values normalized to the amount of
protein in the cell homogenate (Fig. S2). The C16:0 levels were
comparable across the different genotypes when normalizing to
protein (Fig. S2D). The ratio C26:0/C16:0 (Fig. 3B) was increased
in MPMW from Abcd1-deficient mice to a similar extent as that of
C26:0/C22:0 (Fig. 3A). Also the marked increase in C26:0 levels
of Abcd1/Abcd2 double-deficient compared with Abcd1-deficient
cells was obvious in the C26:0/C16:0 ratios (p,0.01) (Fig. 3B).
Whereas the level of C24:0 was only slightly elevated upon Abcd1
deficiency, also this fatty acid accumulated substantially in the
Abcd1/Abcd2 double-deficient MPMW, as indicated by the
C24:0/C22:0 ratio (Fig. 3C) as well as the absolute values (Fig.
S2B). In contrast, the levels of C22:0 were slightly lower in MPMW
from Abcd1-deficient mice, both when expressed as ratio to C16:0
(Fig. 3D) or after normalizing to protein amounts (Fig. S2C), but
the reduction did not reach statistical significance. Interestingly,
there was even a further, statistically significant decrease in the
C22:0/C16:0 ratios in Abcd1/Abcd2 double-deficient MPMW
when compared with wild-type, Abcd1-deficient and Abcd2-
deficient MPMW (Fig. 3D).
Elovl1 mRNA levels of MPMW are not affected by Abcd1
or Abcd2 deficiency
ELOVL1 is responsible for the carbon-chain elongation of
VLCFA (C22:0, C24:0, C26:0). As the marked increase in C26:0
accumulation in Abcd1/Abcd2 double-deficient MPMW compared
with isolated Abcd1 deficiency could be partially, or entirely, due
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to increased elongation of VLCFA, we measured the Elovl1
mRNA levels by qRT-PCR in wild-type and Abcd1/Abcd2 single-
and double-deficient MPMW. After normalization to Hprt mRNA
levels, we observed no difference in Elovl1 mRNA expression in
any of the mutant genotypes (Fig. 4 and Table S2). Thus, at least
at the level of gene expression, Elovl1, encoding the rate limiting
enzyme for elongation of VLCFA, was not upregulated.
Peroxisomal b-oxidation of C26:0 is markedly more
impaired in Abcd1/Abcd2 double-deficient MPMW than in
Abcd1 single deficiency
To establish whether the degradation of VLCFA is impaired in
the different mutant macrophages, we determined the rate of
peroxisomal b-oxidation in MPMW from wild-type, Abcd1-,
Abcd2- and Abcd1/Abcd2 double-deficient mice using radiola-
belled C26:0 as substrate. As a control, and for normalization of
the overall activity of each cell preparation, we measured the rate
of b-oxidation for the LCFA C16:0, which in mammals is
primarily degraded in mitochondria. We found a highly significant
(p,0.001) decrease (38%) in the relative b-oxidation activity for
C26:0 (depicted as ratio to C16:0) in Abcd1-deficient MPMW
compared with wild-type values (Fig. 5). Isolated Abcd2 deficiency
had no statistically significant effect on the capacity for b-oxidation
of either substrate. However, there was a highly significant (p,
0.001) further reduction in the b-oxidation activity for C26:0 in
Abcd1/Abcd2 double-deficient MPMW when compared with
Abcd1-deficient (54%) as well as wild-type (71%) and Abcd2-
deficient (65%) MPMW (Fig. 5). Similar results were obtained
when considering the absolute values of the b-oxidation rates for
C26:0 normalized to the amount of cellular protein in the MPMW
samples (Fig. S4A). The b-oxidation activity for C16:0 was similar
in MPMW of all different genotypes (Fig. S4B).
Discussion
Our results show that primary macrophages from Abcd1/Abcd2
double-deficient mice have a considerably more severe metabolic
phenotype than those with single Abcd1 deficiency, as documented
by a markedly reduced rate of peroxisomal b-oxidation for C26:0
leading to the strongly increased accumulation of saturated
VLCFA (C26:0 and C24:0). Inactivation of Abcd2 alone has no
significant effect on the levels of saturated VLCFA in most murine
tissues including brain, spinal cord and sciatic nerve, which are
affected by the pathology in X-ALD [31], which is also the case in
our Abcd22/2 mouse strain (Forss-Petter, unpublished observa-
tion). One notable exception are the dorsal root ganglia [33],
which may explain the earlier onset of a sensory motor phenotype
in Abcd1/Abcd2 double-deficient and Abcd2 single-deficient mice
compared with Abcd1-deficient mice [31]. Considering that
ubiquitous transgenic overexpression of the murine ABCD2
protein in Abcd1-deficient mice rescued the metabolic impairment
and the motor-behavioural phenotype [31], a more dramatic
phenotype might have been anticipated in Abcd1/Abcd2 double-
mutant mice. However, the additive but not amplified severity of
the metabolic and behavioural deficits might be partially explained
by the rather complementary expression patterns of these two
peroxisomal ABC transporters [41,60,62].
In MPMW, we found both the Abcd1 and Abcd2 mRNAs to be
expressed at relatively low abundance (i.e. estimated to represent
less than 0.01% of the total mRNA molecules and lower than the
level of Hprt mRNA). By qRT-PCR, the steady-state level of the
Abcd1 mRNA was about twice that of Abcd2. Thus, MPMW
constitute a good model system to evaluate the level of Abcd2
expression required to prevent a severe metabolic phenotype upon
Abcd1 deficiency. Our results revealed about twofold higher levels
of VLCFA in Abcd1-deficient MPMW, as judged by the ratio
C26:0/C22:0, in agreement with previous observations [27]. This
is similar to the extent of VLCFA storage in modestly affected
tissues like the liver of X-ALD mice [63]. Interestingly, in Abcd1/
Abcd2 double-deficient MPMW, we found an additional sixfold
increase in accumulation of C26:0 when compared with Abcd1
single-deficiency, which amounted to approximately twelvefold
higher than wild-type levels. In brain and adrenal glands, the
pathologically affected tissues in human X-ALD patients, the
C26:0/C22:0 ratio is elevated up to fourfold in Abcd1-deficient
Figure 2. Endogenous Abcd1 and Abcd2mRNA levels in peritoneal macrophages of wild-type and Abcd1-deficient mice. (A) The Abcd1
and Abcd2 mRNA copy numbers in C57BL/6J wild-type MPMW were determined by qRT-PCR. (B) Comparison of Abcd2 mRNA levels in wild-type (WT)
and Abcd1-deficient (KO) MPMW. The numbers of samples (n) are indicated below the graphs. The graphs indicate mean values 6 SD after
normalization to the level of Hprt mRNA in each sample; n.s., no statistically significant difference.
doi:10.1371/journal.pone.0108655.g002
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mice [15,63]. The extent of VLCFA accumulation in myelin-
enriched tissues, such as spinal cord and sciatic nerve, was
reported to be five to sixfold in Abcd1-deficient mice and was not
further elevated in Abcd1/Abcd2 double-deficient mice [31]. Thus,
the twelvefold accumulation of C26:0 that we observed here in
Abcd1/Abcd2 double-deficient MPMW is indeed remarkably
strong. These results indicate that ABCD2 provides an alternative
transport route across the peroxisomal membrane for saturated
VLCFA destined for b-oxidation, thereby counteracting a more
dramatic accumulation in MPMW lacking functional ABCD1 and
rendering the levels of VLCFA only modestly higher than in wild-
type macrophages.
The increased accumulation of saturated VLCFA in MPMW
from Abcd1/Abcd2 double-deficient mice most likely results from
their strongly decreased capacity (29% of wild-type activity) to
catabolize VLCFA via the peroxisomal b-oxidation pathway.
Thus, also in murine monocyte-derived macrophages, the primary
peroxisomal transporter for saturated VLCFA-CoA is ABCD1.
However, in contrast to human monocytes [41] or human
fibroblasts [7], in the absence of ABCD1, sufficient amounts of
endogenous ABCD2 are present to maintain a substantial b-
oxidation capacity for VLCFA substrates (62% of wild-type b-
oxidation activity for C26:0, Fig. 5). The most likely candidate for
mediating the residual b-oxidation activity (29%) for C26:0 in the
Abcd1/Abcd2 double-deficient MPMW is the third peroxisomal
ABC transporter, ABCD3, in similarity to human X-ALD
fibroblasts [7] and monocytes [41]. Unsaturated long- branched-
chain and dicarboxylic fatty acids were recently shown to be the
preferred substrates for human ABCD3 in a heterologous
expression system, while low activity was obtained with C26:0
[64].
Another possibility to promote accumulation of VLCFA would
be through increased elongation of fatty acids boosting the
biosynthesis of C26:0. The chain length-specific enzyme in this
process is ELOVL1 [12]. In a model based on knock-down of
Abcd1 mRNA in rat B12 oligodendrocytes, elevated Elovl1
mRNA levels were reported to coincide with increased VLCFA
levels [65] indicating an association between VLCFA levels and
the regulation of Elovl1 expression. However, we found no
difference from wild-type levels of Elovl1 mRNA in any of the
mutant MPMW by qRT-PCR. This indicates that regulation at the
level of Elovl1 gene expression is unlikely to account for the
Figure 3. VLCFA levels in wild-type, Abcd1 and Abcd2 single-deficient and Abcd1/Abcd2 double-deficient mouse peritoneal
macrophages. The concentrations of the VLCFA species C26:0, C24:0 and C22:0 and the LCFA C16:0 were determined by GC-MS. The relative
amounts of fatty acids, expressed as ratios: (A) C26:0/C22:0; (B) C26:0/C16:0; (C) C24:0/C22:0 and (D), C22:0/C16:0 were analyzed in mouse peritoneal
macrophages of wild-type (WT), Abcd1-deficient (Abcd1 KO), Abcd2-deficient (Abcd2 KO) and Abcd1/Abcd2 double-deficient (DOKO) mice after 5 days
in culture (n= 3). The graphs indicate geometric means6 SD (asymmetrical). Statistically significant differences are indicated: * p,0.05, ** p,0.01, ***
p,0.001; n.s., no statistically significant difference.
doi:10.1371/journal.pone.0108655.g003
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increased accumulation of VLCFA in Abcd1/Abcd2 double-
deficient MPMW. Although we cannot exclude that altered
enzymatic activity or substrate availability for ELOVL1 plays a
role, a major contribution appears unlikely when considering the
strongly impaired rate of degradation of VLCFA.
Taken together, these results suggest that the additional loss of
Abcd2 in Abcd1 deficiency results in a strikingly more severe
metabolic phenotype in mouse peritoneal macrophages. Although
the Abcd2 mRNA is of low abundance and was present at about
only half the level of the Abcd1 mRNA, in Abcd1 deficiency this
modest endogenous level is apparently sufficient to prevent the
dramatic metabolic phenotype that we observed in Abcd1/Abcd2
double-mutant macrophages. In contrast to primary mouse
peritoneal macrophages, primary human monocytes/macrophag-
es virtually lack ABCD2 gene expression [40,41]. Accordingly, in
human X-ALD monocytes, the metabolic defects such as
accumulation of VLCFA and their degradation by peroxisomal
b-oxidation are comparable to those found in Abcd1/Abcd2
double-deficient rather than Abcd1-deficient peritoneal macro-
phages. In MPMF, the Abcd2 gene is apparently not underlying
the strong repression or silencing that was observed for ABCD2 in
human monocytes. Recently, we obtained evidence showing that
the feasibility to induce ABCD2 depends on the differentiation
state in the human monocyte/macrophage lineage [66]. Whereas
ABCD2 was unresponsive to retinoids in primary CD14+
monocytes, 13-cis-retinoic acid produced a fourfold induction
after in vitro differentiation into macrophages [66].
The difference between human ABCD2 and murine Abcd2
expression in macrophages could potentially be one contributing
factor to the absence of a cerebral inflammatory phenotype in the
mouse model of X-ALD. However, as also Abcd1/Abcd2 double-
deficient mice do not develop demyelinating brain inflammation
(Forss-Petter, unpublished observation) and [31], additional
species differences or other unknown triggers must play a critical
role.
In conclusion, these results provide proof of principle that even
a modest endogenous expression of Abcd2 in macrophages can
largely compensate for Abcd1 deficiency and significantly reduce
the amount of C26:0 in Abcd1-deficient macrophages. Although
these observations cannot be directly translated to human
perivascular or parenchymal macrophages or activated microglia
cells in brain lesions of an X-ALD patient, the results are
encouraging for therapeutic strategies aiming at upregulating
expression of ABCD2. The use of Abcd1 and Abcd2 single and
double-deficient macrophages provides a unique model to
discriminate whether ABCD2 is necessary for any observed effects
of treatment in the macrophage lineage. The marked additional
decrease in the capacity for b-oxidation of VLCFA upon
inactivation of Abcd2 in Abcd1 deficiency implies a strong
synergistic effect of ABCD1 and ABCD2 in this cell type.
Supporting Information
Figure S1 Abcd1 mRNA levels in mouse peritoneal
macrophages from wild-type and Abcd2-deficient mice.
The Abcd1 and Hprt mRNA copy numbers were determined by
qRT-PCR in wild-type (WT) and Abcd2-deficient (Abcd2 KO)
cells. The graphs indicate mean values 6 SD for Abcd1 mRNA
after normalization to the level of Hprt mRNA in each sample
(n=3); n.s., no statistically significant difference.
(TIF)
Figure S2 Absolute fatty acid levels in wild-type, Abcd1-,
Abcd2- and Abcd1/Abcd2 double-deficient mouse peri-
toneal macrophages. The concentrations of the VLCFA
species C26:0, C24:0 and C22:0 and the LCFA C16:0 were
determined by GC-MS in mouse peritoneal macrophages of wild-
type (WT), Abcd1-deficient (Abcd1 KO), Abcd2-deficient (Abcd2
KO) and Abcd1/Abcd2 double-deficient (DOKO) mice after 5
days in culture (n=3). The amounts of fatty acids: (A) C26:0; (B)
C24:0; (C) C22:0 and (D) C16:0 were normalized to the protein
content of each sample. The graphs indicate geometric means 6
Figure 4. Elovl1 mRNA levels in wild-type, Abcd1-, Abcd2-, and
Abcd1/Abcd2 double-deficient mouse peritoneal macrophages.
The Elovl1 mRNA copy numbers were determined by qRT-PCR in total
RNA from mouse peritoneal macrophages of wild-type (WT), Abcd1-
deficient (Abcd1 KO), Abcd2-deficient (Abcd2 KO) and Abcd1/Abcd2
double-deficient (DOKO) mice. The graphs indicate mean values 6 SD
after normalization to the level of Hprt mRNA in each sample (n= 3).
doi:10.1371/journal.pone.0108655.g004
Figure 5. b-Oxidation activity for C26:0 in wild-type, Abcd1-,
Abcd2-, and Abcd1/Abcd2 double-deficient mouse peritoneal
macrophages. The rates of b-oxidation for radiolabelled C26:0 and
C16:0 fatty acid substrates were measured in wild-type (WT), Abcd1-
deficient (Abcd1 KO), Abcd2-deficient (Abcd2 KO) and Abcd1/Abcd2
double-deficient (DOKO) cell preparations. The results are shown as
mean values 6 SD of the ratio between C26:0 and C16:0. The numbers
of samples (n) are indicated below the graphs. Statistically significant
differences are indicated; *** p,0.001.
doi:10.1371/journal.pone.0108655.g005
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SD (asymmetrical). Statistically significant differences are indicat-
ed: * p,0.05, ** p,0.01; n.s., no statistically significant difference.
(TIF)
Figure S3 Relative C26:0 levels in wild-type, Abcd1-,
Abcd2- and Abcd1/Abcd2 double-deficient peritoneal
macrophages cultured for 1-day. The concentrations of
C26:0 and C22:0 were determined by GC-MS in wild-type (WT),
Abcd1-deficient (Abcd1 KO), Abcd2-deficient (Abcd2 KO) and
Abcd1/Abcd2 double-deficient (DOKO) mouse peritoneal macro-
phages after 1 day in culture. The relative amounts of C26:0 are
expressed as C26:0/C22:0 ratio. The graphs indicate geometric
means6 SD (asymmetrical). Statistically significant differences are
indicated: * p,0.05, *** p,0.001; (n=3).
(TIF)
Figure S4 b-Oxidation activity towards C26:0 and C16:0
in wild-type, Abcd1-, Abcd2, and Abcd1/Abcd2 double-
deficient peritoneal macrophages. The absolute rates of b-
oxidation of [14C]-labelled fatty acid substrates for: (A) C26:0 and
(B) C16:0 were measured in wild-type (WT), Abcd1-deficient
(Abcd1 KO), Abcd2-deficient (Abcd2 KO) and Abcd1/Abcd2
double-deficient (DOKO) cells. The results are shown as the
mean values 6 SD of the rate (pmol/min) of released, water-
soluble [14C]-acetyl-CoA normalized to the protein content (mg).
The numbers of samples (n) are indicated below the graphs.
Statistically significant differences are indicated: * p,0.05, ** p,
0.01, *** p,0.001.
(TIF)
Table S1 Absolute and normalized mRNA copy num-
bers of Abcd1, Abcd2 and Hprt determined by qRT-PCR.
(DOCX)
Table S2 Absolute and normalized mRNA copy num-
bers of Elovl1 and Hprt determined by qRT-PCR.
(DOCX)
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